Tyrosine kinase inhibitors (TKIs) have revolutionized the management of several malignancies by selectively targeting aberrant signaling pathways that drive tumor growth and survival. As their clinical use expands, there is a growing need for robust, sensitive, and environmentally sustainable analytical methods to support quality control, pharmacokinetic monitoring, and regulatory compliance. Reversed‑phase high‑performance liquid chromatography (RP‑HPLC) remains the workhorse technique for quantifying TKIs in pharmaceutical formulations and biological matrices; however, conventional RP‑HPLC methods often rely on toxic organic solvents, high flow rates, and energy‑intensive operations, raising concerns about environmental and occupational safety. In response, the concept of “green RP‑HPLC” has emerged, integrating analytical quality‑by‑design (AQbD), solvent substitution, miniaturization, and multi‑metric greenness assessment into method development workflows. This paper presents a comprehensive account of green RP‑HPLC method development for selected TKIs, illustrated with recent data tables, mechanistic diagrams, and quantitative greenness evaluation using tools such as Analytical Eco‑Scale, AGREE, GAPI, and NEMI.
Kumar* et al. (Mon,) studied this question.